0% found this document useful (0 votes)
4 views1 page

Kamala Barman Female21 Years 195625

Uploaded by

manish
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
4 views1 page

Kamala Barman Female21 Years 195625

Uploaded by

manish
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

Name : MRS.

KAMALA BARMAN
Age/ Gender : 21 years / Female Ref. Doctor : SELF
Sample Type : Serum Collected : Aug 27, 2025, 12:24 p.m.
Sample ID : 246009338 Received : Aug 27, 2025, 12:30 p.m.
Client Name : 2WBKOL056 Reported : Aug 27, 2025, 03:01 p.m.

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

25-Hydroxy Vitamin D Total (D2 & D3)


25-Hydroxy Vitamin D Total (D2 & D3) 104.4 ng/mL 20 - 51
(Method: CLIA)

NOTE: The above Given Risk Level Interpretation is not age specific and is an information resource only and is not to be used or relied on for any diagnostic or treatment purposes and

should not be used as a substitute for professional diagnosis and treatment.

METHOD: Electrochemiluminescence binding assay Equipment: Roche Cobas.

VALUE CONDITION INFERENCE

< 10 SEVERE DEFICIENCY Could be associated with osteomalacia or rickets

10 - 19 MILD DEFICIENCY May be associated with increased risk of osteoporosis or secondary hyperparathyroidism

20 - 50 OPTIMUM LEVELS Optimum levels in the healthy population; patients with bone disease may benefit from higher levels within this range

INCREASED Sustained levels >50 ng/mL25OH-VitD along with prolonged calcium supplementationmay lead to hypercalciuria and
51 - 80
Risk of hypercalciuria decreased renal function

80 ng/mL is the lowest reported level associated with toxicity in patients without primary hyperparathyroidism who have

normal renal function. Most patients with toxicity have levels > 150 ng/mL. Patients with renal failure can have very high
>80 TOXICITY POSSIBLE
25-OH-VitD levels without any signs of toxicity, as renal conversion to the active hormone 1, 25-OH-VitD is impaired or

absent.

These reference ranges represent clinical decision values, based on the 2011 Institute of Medicine report, that apply to males and females of all ages, rather than population-based

reference values. Population reference ranges for 25-OH-VitD vary widely depending on ethnic background, age, geographic location of the studied populations, and the sampling season.

NOTE : This sample is processed at HealthMap Diagnostics Pvt Ltd (KOLKATA) Lab.

Page 1 of 1

You might also like